Clinical trials: Urinary Bladder, Overactive
Overactive Bladder, Urinary Urge Incontinence
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge
- Trial name
- NCT05308979
- Testing
- OnabotulinumtoxinA 100 UNT [Botox]
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Overactive Bladder, Urinary Incontinence
Percutaneous Nerve Evaluation With Fluoroscopy Versus Without
The investigators propose a randomized control trial comparing the rate of implantation of the InterStim device following Percutaneous Nerve Evaluation (PNE) performed with or without fluoroscopic guidance.
- Conditions
- Overactive Bladder, Urinary Incontinence, Fecal Incontinence
- Trial name
- NCT02677753
- Testing
- Fluoroscopy
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Overactive Bladder (OAB), Pharmacokinetics of Mirabegron
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
The purpose of this study was to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluated the safety and tolerability of mirabegron in pediatric participants with OAB and…
- Trial name
- Dolphin (NCT04641975)
- Testing
- Mirabegron
- Where
- 15 sites in Belgium, France and 8 more
- Volunteers
- 26 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Parkinson Disease, Overactive Bladder
Mirabegron in Parkinson Disease and Impaired Cognition
There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack of pharmacotherapies with an acceptable side effect profile.
- Conditions
- Parkinson Disease, Overactive Bladder, Impaired Cognition
- Trial name
- MICT-PD (NCT02536976)
- Testing
- mirabegron
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- HealthPartners Institute
Urologic Diseases, Urodynamics
Modern Urodynamics System Efficacy (MUSE) Study
The goal of this prospective trial is to evaluate the feasibility, efficacy, and safety of the Glean Urodynamics System (GUS) for use in the clinic to collect vesical pressure data in adult males and females with lower urinary…
- Trial name
- MUSE (NCT05959655)
- Testing
- Glean Urodynamics System
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Bright Uro
Parkinsons Disease
A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
The purpose of this study is to see if the study drug, Mirabegron, is safe and effective in treating symptoms of Overactive Bladder in people with Parkinson's Disease.
- Trial name
- Maestro (NCT02092181)
- Testing
- Mirabegron
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Daniel Burdick, MD
Urinary Incontinence, Overactive Bladder With Urinary Incontinence
BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
This study will evaluate the efficacy and safety of BOTOX® intravesical instillation in participants with overactive bladder and urinary incontinence.
- Trial name
- APOLLO (NCT03320850)
- Testing
- OnabotulinumtoxinA and Hydrogel admixture
- Where
- 63 sites in United States, Canada
- Volunteers
- 383 people
- Sponsor
- Allergan
Overactive Bladder
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory…
- Trial name
- NCT01178827
- Testing
- trospium chloride, oxybutynin IR
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Allergan
Overactive Bladder
Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS)
Study objectives: To report feasibility data for safety and effectiveness of the study device. Study device: Nine Continents Medical implantable tibial nerve stimulator (ITNS) model 9C-680 with programmer model 9C-580.
- Trial name
- NCT04115228
- Testing
- Implantation and neuromodulation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Nine Continents Medical, Inc.
Overactive Bladder
Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
The purpose of this study is to look for evidence of bacteria in the urine or bladder of people with overactive bladder. Because you do not have overactive bladder, your participation in this study will be used as a comparison to…
- Trial name
- NCT00714792
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Overactive Bladder
Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate
The investigators are studying two FDA-approved modalities used to treat overactive bladder to determine if they improve overactive bladder with or without urge incontinence when used together rather than separately, percutaneous…
- Trial name
- NCT01605617
- Testing
- Fesoterodine fumarate, Percutaneous Tibial Nerve Stimulation (PTNS)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Overactive Bladder
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis.
- Trial name
- NCT00876447
- Testing
- Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 397 people
- Sponsor
- Allergan
Mental Competency, Urinary Bladder, Overactive
The Effect of Anticholinergics on Cognitive Function in the Elderly
Anticholinergic medication is used to treat overactive bladder (OAB). A known side effect of this medication is cognitive dysfunction.
- Conditions
- Mental Competency, Urinary Bladder, Overactive, Cognitive Function
- Trial name
- ACE (NCT01922115)
- Testing
- Trospium Chloride
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Overactive Bladder, Urinary Frequency
FREEOAB Study for Overactive Bladder
This is a prospective, multicenter study that was conducted to evaluate the safety and efficacy of a novel, closed-loop, continuous-sensing wearable neuromodulation system for Overactive Bladder symptom control.
- Conditions
- Overactive Bladder, Urinary Frequency, Urinary Incontinence, Urge, Urinary Urgency
- Trial name
- NCT04547920
- Testing
- Wearable Bladder Modulation System
- Where
- 9 sites in United States
- Volunteers
- 96 people
- Sponsor
- Avation Medical, Inc.